Trial Profile

A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Acronyms SERENITY
Sponsors Eli Lilly and Company

Most Recent Events

06 Feb 2025 Results reporting outcomes and clinical measures with changes in fatigue from baseline to week 104 (W104) published in the Inflammatory Bowel Diseases.
17 Oct 2023 Results assessing efficacy and safety of mirikizumab extending to W104, presented at the 31st United European Gastroenterology Week.
17 Oct 2023 Results assessing IBDQ scores through Week 104, presented at the 31st United European Gastroenterology Week.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com